In this article, we will list the 5 Best Low Volatility Stocks to Buy Under $50. Please visit 10 Best Low Volatility Stocks to Buy Under $50 if you would like to see the extended list and the methodology behind it.

5. Vale S.A. (NYSE:VALE)

Number of Hedge Fund Holders: 50

Vale S.A. (NYSE:VALE) is one of the best low volatility stocks to buy under $50. Scotiabank lifted the price target on Vale S.A. (NYSE:VALE) to $19 from $18 on June 15 and maintained a Sector Perform rating on the shares, telling investors that it is updating the price targets for Metals & Mining stocks under its coverage. The firm further told investors that the copper market is “tighter than you think”, and it anticipates that the new medium-term supply growth is insufficient to balance the market.

In its production and sales results for fiscal Q1 2026, Vale S.A. (NYSE:VALE) announced that multiple assets reached their highest production levels. Production in copper and nickel reached double-digit growth, with copper recording its best first-quarter output since 2017 and nickel since 2020. In addition, in iron ore, the ramp-up of new assets supported consistent production growth, while sales reached the highest level for a first-quarter since 2018.

Vale S.A. (NYSE:VALE) is a global mining and metals company that is based in Rio de Janeiro, Brazil, and has a presence in over 20 countries. It is the world’s largest producer of iron ore and nickel, and it also has operations in manganese, ferroalloys, copper, gold, silver, and cobalt.

4. Truist Financial Corporation (NYSE:TFC)

Number of Hedge Fund Holders: 54

Truist Financial Corporation (NYSE:TFC) is one of the best low volatility stocks to buy under $50. Stephens resumed coverage of Truist Financial Corporation (NYSE:TFC) with an Overweight rating on June 15 and set a price target of $59. The firm resumed coverage of nine super-regional banks and stated that it is “broadly constructive” around the setup for the group. It also noted that the operating leverage has improved over the past year, while the capital return for 2026 is forecasted at levels not seen since 2019 and could accelerate pending the Basel 3 Endgame proposals.

Truist Financial Corporation (NYSE:TFC) also received a rating update from Baird on May 1. The firm downgraded the stock to Neutral from Outperform and kept the price target unchanged at $55 while citing valuation for the downgrade, with the shares up 17% off the March lows. Baird further stated that it sees other banks with better pre-provision net revenue growth trajectories and earnings growth potential, and told investors in a research note that Truist Financial Corporation (NYSE:TFC) “has one of the most attractive franchises in banking, but feels like a sale is unlikely in the near term”.

Truist Financial Corporation (NYSE:TFC) is a financial holding company that provides banking services to individuals, businesses, and municipalities. The company’s operations are divided into the following segments: Consumer Banking and Wealth, Corporate and Commercial Banking, and Other, Treasury and Corporate.

3. Novo Nordisk A/S (NYSE:NVO)

Number of Hedge Fund Holders: 55

Novo Nordisk A/S (NYSE:NVO) is one of the best low volatility stocks to buy under $50. Novo Nordisk A/S (NYSE:NVO) announced on June 11 that the Wegovy® pill has been approved in the UK as an adjunct to a reduced-calorie diet and increased physical activity, offering a first-of-its-kind alternative to injectable treatments for adults. The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) approved the Wegovy® pill. Wegovy is an oral glucagon-like peptide-1 receptor agonist licensed for weight management in adults living with obesity (initial Body Mass Index (BMI) ≥30 kg/m2), or overweight (BMI ≥27 kg/m2 to <30 kg/m2), with at least one weight-related condition.

Sebnem Avsar Tuna, general manager at Novo Nordisk UK, stated that the approval marks a significant milestone for obesity care in the UK, as people living with obesity have access to a GLP-1 treatment in a daily pill for the first time, which allows them “the choice and flexibility of oral treatment to support their long-term weight management”.

Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products.

2. SLB N.V. (NYSE:SLB)

Number of Hedge Fund Holders: 74

SLB N.V. (NYSE:SLB) is one of the best low volatility stocks to buy under $50. Stifel lifted the price target on SLB N.V. (NYSE:SLB) to $64 from $61 on June 18 and maintained a Buy rating on the shares. The rating update came after the company provided an in-depth overview of its deep Digital capabilities and key differentiators at its Digital Investor Day event.

In a separate development, SLB N.V. (NYSE:SLB) announced on June 15 the launch of the SLB Digital Marketplace, which is a curated digital destination specially designed to “help energy companies rapidly discover and deploy specialized AI agents, domain models, skills, tools, data connectors and digital applications within their existing digital environments”. Management stated that the SLB Digital Marketplace extends the company’s open platform strategy to its Tela™ agentic AI assistant by allowing SLB, partners, developers, independent software vendors (ISVs), and customers to “bring purpose-built digital capabilities to the energy industry through a single, governed channel”.

SLB N.V. (NYSE:SLB) provides energy technology and operates through the following business segments: Digital and Integration, Reservoir Performance, Well Construction, and Production Systems.

1. Boston Scientific Corporation (NYSE:BSX)

Number of Hedge Fund Holders: 106

Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, and Barclays wants to take a more conservative view on 2027 medtech company estimates, given valuations are already reflecting utilization risk. It further told investors that the firm is lowering 2027 estimates across its larger-cap coverage where there’s exposure to utilization and inflation.

Boston Scientific Corporation (NYSE:BSX) also received a rating update from Canaccord on June 1. The firm lowered the price target on the stock to $70 from $71, reiterating a Buy rating on the shares. Canaccord stated that it updated its model on the stock to take into account slowdowns in the U.S. Watchman business in 2026 and 2027, which have negative implications on its revenue and EPS estimates.

Boston Scientific Corporation (NYSE:BSX) manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments. The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.